DuPont develops second-generation contrast agent
This article was originally published in Clinica
DuPont has submitted a new drug application (NDA) to the FDA for Definity (perflutren), its second-generation contrast agent for ultrasound imaging. Formerly known as DMP 115, the contrast agent is one of several being developed that are based on small gas-filled bubbles. Others include MBI's Optison and Sonus Pharmaceuticals' Echogen.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.